Immix Biopharma, Inc. IMMX

– Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after ded

Immix Biopharma’s latest clinical results showed strong patient responses to its lead CAR-T candidate as the biotech firm prepares for a planned regulatory filing in 2027.

Immix Biopharma, Inc. (NASDAQ:IMMX) reported interim data from its NEXICART-2 Phase 2 clinical trial of NXC-201 in patients with relapsed or refractory AL amyloidosis.

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Compan

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) – – To-date, all patients achieving MRD-negativity reached CR within one year of treatment – – Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee – – In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to

LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference being held September 14-16, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Morgan

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that exhibit strong innovation potential and robust financial health to capitalize on future opportunities.

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting

LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to c

– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patients who have reached CR – – All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month – – Next NEXICART-2 Update Expected Late September, 2026 – LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixB

Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and potential for substantial earnings expansion.

Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regulatory approval for NXC-201. This therapy targets relapsed/refractory AL Amyloidosis, a condition where the immune system produces toxic proteins […]